SC 13G 1 viro13g080802.txt VIROPHARMA 13G 080802 =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ViroPharma Incorporated --------------------------------------- (Name of Issuer) COMMON STOCK, $.002 PAR VALUE --------------------------------------------------------------------------- (Title of Class of Securities) VP 03418 ----------------- (CUSIP Number) August 1, 2002 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ x] Rule 13d-1(c) [ ] Rule 13d-1(d) =========================================================================== Page 1 of 8 There are no Exhibits CUSIP No. VP 03418 1) Name of Reporting Person and its Aventis Inc. I.R.S. Identification Number 23-1699163 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] 3) SEC Use Only 4) Citizenship or Place of Organization Pennsylvania 5) Sole Voting Power 3,000,000 Number of _____________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by _____________________________________________ Each Reporting 7) Sole Dispositive Power 3,000,000 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 3,000,000 by Each Reporting Person ________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ________________________________________________________________________ 11) Percent of Class Represented 11.7% by Amount in Row (9) ________________________________________________________________________ 12) Type of Reporting Person CO ________________________________________________________________________ CUSIP No. VP 03418 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 13-2563649 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 3,000,000 Number of ________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ________________________________________________ Each Reporting 7) Sole Dispositive Power 3,000,000 Person With________________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 3,000,000 by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 11.7% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ < CUSIP No. VP 03418 1) Name of Reporting Person and its Aventis Holdings Inc. I.R.S. Identification Number 51-0414396 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] 3) SEC Use Only 4) Citizenship or Place of Organization Delaware 5) Sole Voting Power 3,000,000 Number of ___________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ___________________________________________________ Each Reporting 7) Sole Dispositive Power 3,000,000 Person With___________________________________________________________________ 8) Shared Dispositive Power 0 _____________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 3,000,000 by Each Reporting Person _____________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares _____________________________________________________________________________ 11) Percent of Class Represented 11.7% by Amount in Row (9) _____________________________________________________________________________ 12) Type of Reporting Person CO _____________________________________________________________________________ PAGE> CUSIP No. VP 03418 ITEM 1(a). NAME OF ISSUER: --------- ------------------------- ViroPharma Incorporated ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: -------- --------------------------------------------------------------- 405 Eagleview Blvd. Exton, Pennsylvania 19341 ITEM 2(a).-(c) NAME OF PERSON FILING AND ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: ------------ --------------------------------------------------------------- (a) - (c) This Schedule is filed on behalf of Aventis Pharmaceuticals Inc. ("API") with a principal place of business and principal office located at 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807. . API is an indirect subsidiary of Aventis S.A., a French corporation ("Aventis") headquartered in Strasbourg, France. This Schedule also is filed on behalf of Aventis Holdings Inc., a Delaware corporation ("AHI"), which owns a 100% of the equity of API. AHI also is an indirect subsidiary of Aventis. The principal place of business and principal office of AHI is 3711 Kenneth Pike, Suite 200 Greenville, Delaware 19801. AHI is filing this Schedule solely with respect to its potential deemed indirect ownership of the Issuer's stock owned by API. This Schedule also is filed on behalf of Aventis Inc., a Pennsylvania corporation ("AI"), which owns 100% of the equity of AHI. 100% of the equity of AI is held by Aventis, a portion of which is held directly and a portion of which is held indirectly. The principal place of business and principal office of AI is 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807. AI is filing this Schedule solely with respect to its potential deemed indirect ownership of the Issuer's stock owned by API. ITEM 2(d). TITLE OF CLASS OF SECURITIES: ----------- ---------------------------------------------- Common Stock, $.002 Par Value ITEM 2(e): CUSIP NUMBER: --------- --------------------- VP 03418 CUSIP No. VP 03418 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR 13D-2(b) ------------------------------------------------------------------------------- Not Applicable ITEM 4. OWNERSHIP: --------- ----------------- (a): AMOUNT BENEFICIALLY OWNED: 3,000,000 Shares Of Common Stock. (b): PERCENT OF CLASS: 11.7% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 3,000,000 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the isposition of: 3,000,000 (iv) Shared power to dispose or to direct the disposition of: 0 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS ------- ------------------------------------------------------------------ Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. ------- ------------------------------------------------------------------- Not Applicable 7 CUSIP No. VP 03418 ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY ------ ---------------------------------------------------------------------- Not applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP ------- ------------------------------------------------------------------ Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. ------- ------------------------------------------------------------------- Not Applicable ITEM 10. CERTIFICATION. -------- ----------------------- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. VP 03418 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: August 8, 2002 By: /s/Edward H. Stratemeier Edward H. Stratemeier Vice President After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS HOLDINGS INC. Date: August 8, 2002 By: /s/Phillip R. Ridolfi Phillip R. Ridolfi President After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS INC. Date: August 8, 2002 By: /s/Edward H. Stratemeier Edward H. Stratemeier Vice President